Buy Survodutide 10mg: Dual Glucagon/GLP-1 Receptor Agonist for Metabolic Research

Survodutide (10mg) is an investigational synthetic dual glucagon and GLP-1 receptor agonist (BI 456906) extensively studied for its effects on obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH). Research from phase 2 trials highlights its role in promoting significant weight loss (up to ~19% in some models), improving insulin sensitivity, reducing hepatic fat content, decreasing inflammation and fibrosis in liver models, increasing energy expenditure, and offering potential cardiovascular and metabolic benefits. This research-grade peptide, supplied in a 10mg vial with 99% purity, is ideal for investigating incretin/glucagon dual agonism, appetite regulation, lipolysis, hepatic health, and body composition in experimental settings.

Molecular Formula: C192H289N47O61 Molecular Weight: 4232 g/mol Purity: 99%

Important Notice: This peptide is strictly intended for research and laboratory use only. Not for human consumption, diagnostic, therapeutic, or veterinary purposes. Please review and agree to our Terms and Conditions before placing an order.

What is Survodutide?

Survodutide is a long-acting unimolecular peptide analog derived from glucagon with modifications for dual activity at glucagon (GCGR) and GLP-1 receptors. Unlike single GLP-1 agonists, its dual mechanism combines GLP-1-mediated appetite suppression and glucose control with glucagon-driven energy expenditure and hepatic lipid metabolism.

Phase 2 trials (e.g., in obesity without diabetes and MASH with fibrosis) demonstrated dose-dependent efficacy, with higher doses achieving superior outcomes in weight reduction, liver fat clearance (>30% reduction in many participants), and histologic MASH improvement without fibrosis worsening.

The 10mg vial supports mid-range dosing simulations, reconstitution flexibility, and extended experimental use.

Mechanism of Action

Survodutide activates both receptors to:

• Suppress appetite and slow gastric emptying via GLP-1 pathway
• Increase energy expenditure and promote lipolysis via glucagon signaling
• Reduce hepatic fat accumulation and inflammation
• Improve glycemic control and insulin sensitivity
• Support reductions in body weight, waist circumference, and cardiometabolic risk factors

This balanced dual agonism may provide advantages over GLP-1-only therapies, particularly in liver fat metabolism and sustained weight loss.

Key Research Findings and Benefits

Survodutide stands out in metabolic and hepatology research.

Weight Loss and Obesity Models

Trials report dose-dependent reductions (up to ~19% at higher doses over 46 weeks), with many participants achieving ≥20% loss and no plateau in some analyses.

MASH and Liver Health

In MASH/fibrosis models, survodutide improved histology (MASH resolution without fibrosis worsening in up to 62% at certain doses), reduced liver fat by ≥30% in most, and showed antifibrotic/anti-inflammatory effects.

Metabolic and Cardiovascular Support

Studies indicate favorable changes in lipids, blood pressure, and other risk factors, supporting broader cardio-renal-metabolic investigations.

Research Applications

The 10mg format supports:

• Obesity and overweight experimental models
• MASH/liver fibrosis and steatohepatitis studies
• Dual incretin/glucagon pathway, energy expenditure, and hepatic lipid metabolism research
• Dose-response, pharmacokinetics, and long-term exposure simulations

Reconstitution example (lab protocols vary): Use bacteriostatic water to prepare concentrations for weekly administration analogs.

Why Choose 99% Pure Survodutide 10mg?

Our survodutide 10mg offers ≥99% purity for reliable, reproducible results in receptor activation, metabolic endpoints, and liver histology studies. Vacuum-sealed and third-party tested to ensure consistency.

In summary, Survodutide 10mg is a cutting-edge dual agonist peptide for pioneering research into obesity management, weight loss, MASH resolution, hepatic fat reduction, and metabolic optimization. Explore its dual glucagon/GLP-1 potential in your laboratory today.

Latest Testing: Link to Report